

From: [REDACTED]@sanofi.com>
Sent: 25 June 2020 08:48
To: [REDACTED] (SG-RECOVER); [REDACTED] (SANTE);
GALLINA Sandra (SANTE); [REDACTED]@pm.gouv.fr;
[REDACTED]@sanita.it; [REDACTED] (SG-RECOVER);
[REDACTED] (SJ); [REDACTED] (SG)
Cc: [REDACTED]
Subject: RE: Vaccines - follow-up
Attachments: 20200625-Meeting EU_Sanofi GSK COVID vaccine-vPresentation.pdf

Dear all,
Please find enclosed the final version to be used during our presentation at 10:00AM. Thanks
Best regards
[REDACTED]

De : [REDACTED]
Envoyé : mercredi 24 juin 2020 21:45
À : [REDACTED]@ec.europa.eu; [REDACTED]@ec.europa.eu>;
[REDACTED]@ec.europa.eu; Sandra.Gallina@ec.europa.eu;
[REDACTED]@ec.europa.eu; [REDACTED]@ec.europa.eu;
[REDACTED]@ec.europa.eu
Cc : [REDACTED]@sanofi.com>; [REDACTED]
[REDACTED]@sanofi.com>; [REDACTED]@sanofi.com>;
[REDACTED]@sanofi.com>
Objet : RE: Vaccines - follow-up

Dear all,
As agreed, please find enclosed pre-reads for our meeting tomorrow at 10:00AM CET.
The slideset has been built to address the questions we received from you, providing further details on the joint Sanofi-GSK term sheet.
Looking forward to our discussion.
Best regards
[REDACTED]

De : [REDACTED]@ec.europa.eu; [REDACTED]@ec.europa.eu>
Envoyé : mardi 23 juin 2020 16:15
À : [REDACTED]@sanofi.com>
Cc : [REDACTED]@ec.europa.eu; Sandra.Gallina@ec.europa.eu; j
[REDACTED]@pm.gouv.fr; [REDACTED]@sanita.it; [REDACTED]@ec.europa.eu;
[REDACTED]@ec.europa.eu; [REDACTED]@ec.europa.eu
Objet : [EXTERNAL] Vaccines - follow-up

EXTERNAL : Real sender is [REDACTED]@ec.europa.eu

Dear [REDACTED]

Following up on our recent communication, we have now gathered some more points from our colleagues from the Member States on which we would need further information. We have included all the points in the document attached, including the comments and questions which we have shared with you before. As discussed, it would be good to receive some comments and replies in advance of the meeting, now envisaged for Thursday.

Kind regards,

[REDACTED]